Overview

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Status:
RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.

Phase:

PHASE2

Details

Lead Sponsor:

Biocad